Financial Results at Ipsen | Detailed Financial Performance

Financial Results

Latest Financial Results

Filter

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 29 Financial Results

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business
 –  11 February 2022

11 February 2022

Download
Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

Attachment


Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
 –  17 December 2021

17 December 2021

Download
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership


Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
 –  17 December 2021

17 December 2021

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership


Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance
 –  21 October 2021

21 October 2021

Download
Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance


Ipsen delivers strong H1 2021 results and upgrades full-year guidance
 –  26 July 2021

26 July 2021

Download
Ipsen delivers strong H1 2021 results and upgrades full-year guidance


Your dedicated contacts